Christopher Ballas, PhD, Innovative Cellular Therapeutics, Rockville, MD, comments on progress in evaluating CoupledCAR, a chimeric antigen receptor (CAR) T-cell therapy designed for solid tumors, in colorectal cancer. The investigational CAR T-cell therapy targets the antigen guanylate cyclase 2C (GCC) and whilst it is also expressed in normal tissue, targeting GCC has proven to be safe. Institutional Review Board (IRB) trials have demonstrated promising efficacy in patients in the third line setting. Dr Ballas additionally highlights how the target can be altered to treat alternative indications such as thyroid and prostate cancer. This interview took place at Advanced Therapies Week 2022.
